The multi-functionality of CD40L and its receptor CD40 in atherosclerosis

Summary

Disrupting the CD40-CD40L co-stimulatory pathway reduces atherosclerosis and induces a stable atherosclerotic plaque phenotype that is low in inflammation and high in fibrosis. Therefore, inhibition of the CD40-CD40L pathway is an attractive therapeutic target to reduce clinical complications of atherosclerosis. The CD40-CD40L dyad is known to interact with other costimulatory molecules, to activate antigen-presenting cells (APC) and to contribute to T-cell priming and B-cell isotype switching. Besides their presence on T-cells and APCs, CD40 and CD40L are also present on macrophages, endothelial cells and vascular smooth muscle cells in the plaque, where they can exert pro-atherogenic functions. Moreover, recent progress indicates the involvement of neutrophil CD40, platelet CD40L and dendritic cell CD40 in atherogenesis. Since systemic CD40-CD40L modulation compromises host defense, more targeted interventions are needed to develop superior treatment strategies for atherosclerosis. We believe that by unravelling the cell-cell CD40-CD40L interactions, inhibition of cell-type specific (signalling components of) CD40(L) that do not compromise the patient’s immune system, will become possible. In this review, we highlight the cell-type specific multi-functionality of CD40-CD40L signalling in atherosclerosis.

Keywords

Atherosclerosis - immunity - inflammation - co-stimulation - TNF receptor-associated factor

• References

• 1 Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-241.
• 2 Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 06: 508-519.
• 3 Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-126.
• 4 Weber C. et al. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008; 08: 802-815.
• 5 Passlick B. et al. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood 1989; 74: 2527-2534.
• 6 Swirski FK. et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007; 117: 195-205.
• 7 Weber C. et al. Differential chemokine receptor expression and function in human monocyte subpopulations. J Leukoc Biol 2000; 67: 699-704.
• 8 Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 05: 953-964.
• 9 Robertson AK, Hansson GK. T cells in atherogenesis: for better or for worse?. Arterioscler Thromb Vasc Biol 2006; 26: 2421-2432.
• 10 van Leeuwen M. et al. Accumulation of myeloperoxidase-positive neutrophils in atherosclerotic lesions in LDLR-/-mice. Arterioscler Thromb Vasc Biol 2008; 28: 84-89.
• 11 Soehnlein O. et al. Neutrophil secretion products pave the way for inflammatory monocytes. Blood 2008; 112: 1461-1471.
• 12 Bot I. et al. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. Circulation 2007; 115: 2516-2525.
• 13 Sun J. et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med 2007; 13: 719-724.
• 14 Bobryshev YV. Dendritic cells in atherosclerosis: current status of the problem and clinical relevance. Eur Heart J 2005; 26: 1700-1704.
• 15 Massberg S. et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002; 196: 887-896.
• 16 Huo Y. et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 09: 61-67.
• 17 Noelle RJ. et al. CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation. Immunol Today 1992; 13: 431-433.
• 18 Ludewig B. et al. Induction, regulation, and function of soluble TRAP (CD40 ligand) during interaction of primary CD4+ CD45RA+ T cells with dendritic cells. Eur J Immunol 1996; 26: 3137-3143.
• 19 Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res 2001; 89: 1092-1103.
• 20 Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86: 515-581.
• 21 Kleemann R. et al. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008; 79: 360-376.
• 22 Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354: 610-621.
• 23 Zernecke A. et al. Chemokines in Atherosclerosis. An Update. Arterioscler Thromb Vasc Biol 2008; 28: 1897-1908.
• 24 Bruemmer D. et al. Expression of CD40 in vascular smooth muscle cells and macrophages is associated with early development of human atherosclerotic lesions. Am J Cardiol 2001; 87: 21-27.
• 25 Hakkinen T. et al. Macrophages, smooth muscle cells, endothelial cells, and T-cells express CD40 and CD40L in fatty streaks and more advanced human atherosclerotic lesions. Colocalization with epitopes of oxidized low-density lipoprotein, scavenger receptor, and CD16 (Fc gammaRIII). Virchows Arch 2000; 437: 396-405.
• 26 Mach F. et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997; 94: 1931-1936.
• 27 Lutgens E. et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999; 05: 1313-1316.
• 28 Lutgens E, Daemen MJ. CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med 2002; 12: 27-32.
• 29 Lutgens E. et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci USA 2000; 97: 7464-7469.
• 30 Mach F. et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998; 394: 200-203.
• 31 Schonbeck U. et al. CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol 2000; 156: 7-14.
• 32 Schonbeck U. et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci USA 2000; 97: 7458-7463.
• 33 Davis Jr. JC. et al. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 95-101.
• 34 Dumont FJ. IDEC-131. IDEC/Eisai. Curr Opin Investig Drugs 2002; 03: 725-734.
• 35 Schuler W. et al. Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation. Transplantation 2004; 77: 717-726.
• 36 Pearson TC. et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 2002; 74: 933-940.
• 37 Imai A. et al. A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys. Transplantation 2007; 84: 1020-1028.
• 38 Lu LF. et al. The in vivo function of a noncanonical TRAF2-binding domain in the C-terminus of CD40 in driving B-cell growth and differentiation. Blood 2007; 110: 193-200.
• 39 Ahonen C. et al. The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells. Nat Immunol 2002; 03: 451-456.
• 40 Lutgens E. et al. CD40 and its ligand in atherosclerosis. Trends Cardiovasc Med 2007; 17: 118-123.
• 41 Chen Y. et al. Internalization of CD40 regulates its signal transduction in vascular endothelial cells. Biochem Biophys Res Commun 2006; 345: 106-117.
• 42 Donners MM. et al. The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling. Blood 2008; 111: 4596-4604.
• 43 Grewal IS, Flavell RA. CD40 and CD154 in cellmediated immunity. Annu Rev Immunol 1998; 16: 111-135.
• 44 Gotsman I. et al. T-cell costimulation and coinhibition in atherosclerosis. Circ Res 2008; 103: 1220-1231.
• 45 Kumanogoh A. et al. Increased T cell autoreactivity in the absence of CD40-CD40 ligand interactions: a role of CD40 in regulatory T cell development. J Immunol 2001; 166: 353-360.
• 46 Smook ML. et al. Leukocyte CD40L deficiency affects the CD25(+) CD4 T cell population but does not affect atherosclerosis. Atherosclerosis 2005; 183: 275-282.
• 47 Buono C, Lichtman AH. Co-stimulation and plaque-antigen-specific T-cell responses in atherosclerosis. Trends Cardiovasc Med 2004; 14: 166-172.
• 48 Matthies KM. et al. Differential regulation of soluble and membrane CD40L proteins in T cells. Cell Immunol 2006; 241: 47-58.
• 49 Munroe ME, Bishop GA. A costimulatory function for T cell CD40. J Immunol 2007; 178: 671-682.
• 50 Bourgeois C. et al. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 2002; 297: 2060-2063.
• 51 Bavendiek U. et al. Atherogenesis in mice does not require CD40 ligand from bone marrow-derived cells. Arterioscler Thromb Vasc Biol 2005; 25: 1244-1249.
• 52 Aruffo A. et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 1993; 72: 291-300.
• 53 Smook ML. et al. Anti-oxLDL antibody isotype levels, as potential markers for progressive atherosclerosis in APOE and APOECD40L mice. Clin Exp Immunol. 2008 ((please complete reference))
• 54 Hill A, Chapel H. X-linked immunodeficiency. The fruits of cooperation. Nature 1993; 361: 494.
• 55 Caligiuri G. et al. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 2002; 109: 745-753.
• 56 Binder CJ. et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 2004; 114: 427-437.
• 57 Cella M. et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184: 747-752.
• 58 Schonbeck U, Libby P. The CD40/CD154 receptor/ ligand dyad. Cell Mol Life Sci 2001; 58: 4-43.
• 59 Peng X. et al. IL-12 up-regulates CD40 ligand (CD154) expression on human T cells. J Immunol 1998; 160: 1166-1172.
• 60 Mehlhop PD. et al. CD40L, but not CD40, is required for allergen-induced bronchial hyperresponsiveness in mice. Am J Respir Cell Mol Biol 2000; 23: 646-651.
• 61 Zirlik A. et al. CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation 2007; 115: 1571-1580.
• 62 Mach F. et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 1997; 96: 396-399.
• 63 Thim T. et al. From vulnerable plaque to atherothrombosis. J Intern Med 2008; 263: 506-516.
• 64 Fitzgerald DJ. et al. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-989.
• 65 May AE. et al. Platelets: inflammatory firebugs of vascular walls. Arterioscler Thromb Vasc Biol 2008; 28: s5-10.
• 66 Gawaz M. et al. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-3384.
• 67 von Hundelshausen P. et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001; 103: 1772-1777.
• 68 von Hundelshausen P. et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 2005; 105: 924-930.
• 69 Henn V. et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-594.
• 70 Dole VS. et al. Activated platelets induce Weibel-Palade-body secretion and leukocyte rolling in vivo: role of P-selectin. Blood 2005; 106: 2334-2339.
• 71 Furman MI. et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998; 31: 352-358.
• 72 van Gils JM. et al. Transendothelial migration drives dissociation of plateletmonocyte complexes. Thromb Haemost 2008; 100: 271-279.
• 73 Marx N. et al. Induction of cytokine expression in leukocytes in acute myocardial infarction. J Am Coll Cardiol 1997; 30: 165-170.
• 74 Heeschen C. et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104-1111.
• 75 Andre P. et al. CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism. Nat Med 2002; 08: 247-252.
• 76 Andre P. et al. Platelet-derived CD40L: the switchhitting player of cardiovascular disease. Circulation 2002; 106: 896-899.
• 77 Henn V. et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98: 1047-1054.
• 78 Menchen L. et al. Matrix metalloproteinase 9 is involved in Crohn’s disease-associated platelet hyperactivation through the release of soluble CD40 ligand. Gut. 2008 epub ahead of print..
• 79 Chen C. et al. Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells. Blood 2008; 112: 3205-3216.
• 80 Danese S. et al. Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J Immunol 2004; 172: 2011-2015.
• 81 Crist SA. et al. Nuclear factor of activated T cells (NFAT) mediates CD154 expression in megakaryocytes. Blood 2008; 111: 3553-3561.
• 82 Zernecke A. et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res 2008; 102: 209-217.
• 83 Vanichakarn P. et al. Neutrophil CD40 enhances platelet-mediated inflammation. Thromb Res 2008; 122: 346-358.
• 84 Li G. et al. CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury. Am J Pathol 2008; 172: 1141-1152.
• 85 Loskog A. et al. Dendritic cells engineered to express CD40L continuously produce IL12 and resist negative signals from Tr1/Th3 dominated tumors. Cancer Immunol Immunother 2006; 55: 588-597.
• 86 Kobayashi T. et al. The role of TRAF6 in signal transduction and the immune response. Microbes Infect 2004; 06: 1333-1338.
• 87 Kuwajima S. et al. Interleukin 15-dependent crosstalk between conventional and plasmacytoid dendritic cells is essential for CpG-induced immune activation. Nat Immunol 2006; 07: 740-746.
• 88 Auffray C. et al. Blood Monocytes: Development, Heterogeneity, and Relationship with Dendritic Cells. Annu Rev Immunol 2009; 27: 669-692.
• 89 Karmann K. et al. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA 1995; 92: 4342-4346.
• 90 Wagner AH. et al. CD154/CD40-mediated expression of CD154 in endothelial cells: consequences for endothelial cell-monocyte interaction. Arterioscler Thromb Vasc Biol 2004; 24: 715-720.
• 91 Stout RD, Suttles J. The many roles of CD40 in cellmediated inflammatory responses. Immunol Today 1996; 17: 487-492.
• 92 Rizvi M. et al. CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends Mol Med 2008; 14: 530-538.
• 93 Urbich C. et al. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 2002; 106: 981-986.
• 94 Cipollone F. et al. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 2005; 48: 1216-1224.
• 95 Bavendiek U. et al. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem 2002; 277: 25032-25039.
• 96 Zirlik A. et al. TRAF-1, -2, -3, -5, and -6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells. Arterioscler Thromb Vasc Biol 2007; 27: 1101-1107.
• 97 Hermann A. et al. CD40 ligand (CD40L) does not stimulate proliferation of vascular smooth muscle cells. Eur J Cell Biol 2002; 81: 213-221.
• 98 Mukundan L. et al. CD40-mediated activation of vascular smooth muscle cell chemokine production through a Src-initiated, MAPK-dependent pathway. Cell Signal 2004; 16: 375-384.
• 99 Schonbeck U. et al. Ligation of CD40 activates interleukin 1beta-converting enzyme (caspase-1) activity in vascular smooth muscle and endothelial cells and promotes elaboration of active interleukin 1beta. J Biol Chem 1997; 272: 19569-19574.
• 100 Horton DB. et al. Ligation of CD40 onvascular smooth muscle cells mediates loss of interstitial collagen via matrix metalloproteinase activity. Ann NY Acad Sci 2001; 947: 329-336.
• 101 Newby AC. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med 2007; 17: 253-258.
• 102 Packard RR. et al. CD11c(+) dendritic cells maintain antigen processing, presentation capabilities, and CD4(+) T-cell priming efficacy under hypercholesterolemic conditions associated with atherosclerosis. Circ Res 2008; 103: 965-973.
• 103 Leveille C. et al. CD40 ligand binds to alpha5beta1 integrin and triggers cell signaling. J Biol Chem 2007; 282: 5143-5151.